Previous studies indicate that the anti-craving substance acamprosate modulates nucleus accumbens (nAc) dopamine levels via a dopamine-controlling nAc-VTA-nAc neurocircuitry. It was demonstrated that glycine receptors in the nAc are involved both in the dopamine-elevating effect and the ethanol intake-reducing effect of the drug. Here we wanted to explore the interaction of ethanol and acamprosate on nAc dopamine and investigate whether dopaminergic transmission may be related to the ethanol intake-reducing effects. In three separate studies we investigated nAc extracellular dopamine levels by means of in vivo microdialysis after administration of acamprosate and ethanol in 1) naïve rats, 2) rats pre-treated with acamprosate for two days or 3) ethanol medium-and high-preferring rats receiving ten days of acamprosate pre-treatment. In the first two studies, acamprosate elevated dopamine and simultaneously prevented ethanol from further increasing dopamine output. In the third study, long-term acamprosate pre-treatment produced a loss of the ethanol intakereducing as well as the dopamine-elevating effects of acamprosate, and the dopamine elevating property of ethanol was restored. We suggest that acamprosate may partly substitute for the dopamine-elevating effect of ethanol but once tolerance develops to this effect, the ability to decrease ethanol intake is lost.
Introduction
Alcohol addiction is a chronic brain disorder manifested by neuronal alterations i.a. in the mesolimbic dopamine system, an important part of the brain reward pathway (Koob and Nestler, 1997; Wise and Rompre, 1989; Spanagel, 2009) . It has been established that administration of alcohol (ethanol) activates the dopamine system, resulting in an increase of dopamine in various areas of the brain of which the nucleus accumbens (nAc) has gained most interest (Berridge et al., 2009; Wise, 2004) . One of the pharmacotherapies used to treat alcoholism is acamprosate (calcium-bis(N-acetylhomotaurinate); Campral®) (Littleton, 1995; Mason, 2015) . In the rat, acamprosate was demonstrated to increase nAc dopamine (Olive et al., 2002; Cano-Cebrián et al., 2003) , an effect similar to that of ethanol, which was hypothesized to contribute to the drug's ethanol intake-reducing effect (Cowen et al., 2005) . However, several mechanisms of action underlying acamprosate's anti-alcohol effect have been forwarded, including interaction with GABAergic neurotransmission (Boismare et al., 1984; Daoust et al., 1992) or interaction with glutamatergic neurotransmission by direct or indirect modulation of NMDA or mGluR receptors (al Qatari et al., 1998; Naassila et al., 1998; De Witte et al., 2005; Blednov and Harris, 2008) . Recently it was suggested that N-acetylhomotaurinate is a biologically inactive molecule and that it rather is the calcium moiety of acamprosate (calcium-bis(N-acetylhomotaurinate) that is the active ingredient (Spanagel et al., 2014) .
In the search for the mechanism underlying ethanol's ability to increase nAc dopamine we found the amino acid taurine, nAc glycine receptors (GlyR) and ventral tegmental nicotinic acetylcholine receptors (nAChR) to be key components (Ericson et al., 2006; Söderpalm et al., 2017, review; Adermark et al., 2011; Ericson et al., 2011) . Since acamprosate is a homotaurine analogue sharing structural similarities not only with GABA, but also with taurine, an endogenous ligand of the GlyR, we explored in a series of studies whether the dopamine elevating properties of acamprosate and ethanol displayed any similarities. We found that acamprosate, either after systemic or local administration, increased nAc dopamine and that the effect involved GlyRs in the nAc and nAChRs in the VTA (Chau et al., 2010a) . This was identical to what we previously had found when studying taurine (Ericson et al., 2006; Ericson et al., 2011) and ethanol (Blomqvist et al., 1993; Blomqvist et al., 1997; Ericson et al., 2003; Molander and Söderpalm, 2005) individually. When continuing to explore the functional importance of nAc GlyRs in the ethanol intake-reducing effect of acamprosate we were able to reverse the acamprosate-induced decrease in ethanol intake by pre-treatment with the competitive GlyR antagonist strychnine in the nAc (Chau et al., 2010b) . This mechanism of action would then explain the effect of acamprosate also at the behavioral level in the rat. Thus, although several mechanisms of action have been suggested to underlie the ethanol intake-reducing effect of acamprosate, the link between ethanol, acamprosate and dopamine appears to be of importance.
Interestingly, the anti-alcohol effect of acamprosate appears to decline with long-term treatment, at least in rodents, and it was suggested that repeated administration produces tolerance towards the ethanol intake-reducing effect of the compound (Cowen et al., 2005; Vengeliene et al., 2010; Lidö et al., 2012) . The underlying mechanism for this is currently unknown but was suggested to derive from interference either with dopaminergic or glutamatergic neurotransmission. Furthermore, acute administration of acamprosate was found to increase dopamine transporter binding and decrease dopamine D2-like binding in the nAc, whereas after repeated acamprosate administration the binding levels returned to normal (Cowen et al., 2005) . If repeated administration of acamprosate induces neuronal adaptations diminishing its effect, it appears highly relevant from a clinical perspective to further address and understand these events.
In the present study we aimed to evaluate the effects of acute and repeated administration of acamprosate on ethanol-induced dopamine output in the nAc in relation to development of tolerance towards the ethanol intake-reducing effect of acamprosate. Three in vivo microdialysis experiments investigating the interaction between acamprosate and ethanol on dopamine output were performed. In the first experiment, we aimed to determine the nAc dopamine levels following acute local administration of both acamprosate and ethanol in drug-naïve rats. In the second experiment, we aimed to determine the nAc dopamine levels following systemic administration of both acamprosate and ethanol in animals pre-treated two days with acamprosate. And, in the last experiment, we aimed to determine the nAc dopamine response following systemic administration of both acamprosate and ethanol in ethanol medium-and high-preferring rats treated with acamprosate or vehicle for ten days.
Material and methods

Animals
In Experiment 1 and 2, male Wistar rats (n = 59, B&K Universal AB Scanbur, Sollentuna, Sweden or Taconic, Denmark) weighing 290-330 g, were used. Upon arrival, the rats were housed in groups of four in a humidity -(60%) and temperature -(21°C) controlled room on a 12/12 h light/dark cycle (on 07:00 off 19:00), with free access to rodent chow (Harlan Teklad Europe, UK) and tap water. Animals were allowed to adapt for at least seven days to the animal maintenance facilities prior to the start of the experiments. In the third experiment male Wistar rats (n = 33, Taconic, Denmark) weighing 250-280 g were used. These rats were initially housed in groups of four and later in single cages in climate-controlled rooms as described above, except the light cycle was reversed (on 20:00 off 08:00). The reversed light cycle was used in order to monitor ethanol consumption (for details see below) during the rats' active period, performing in vivo microdialysis under these conditions has previously not been found to influence the dopamine output. As in the other experiments, the rats had free access to regular rodent chow and water and were allowed to adapt for at least a week prior to initiation of ethanol screening. All experiments were conducted according to the Declaration of Helsinki and were approved by the Ethics Committee for Animals Experiments (Gothenburg, Sweden).
Drugs and chemicals
Acamprosate (kindly provided by Merck, Lyon, France) was dissolved in Ringer solution when perfused into the nAc or in 0.9% NaCl when administered systemically (i.p.). 95% ethanol (Svensk sprit AB, Sweden) was diluted in Ringer solution when administered locally, 0.9% NaCl when administered systemically (i.p.) or in tap water, when administered intragastrically or in the drinking bottle. The content of the Ringer solution was (in mmol/l): 140 NaCl, 1.2 CaCl 2 , 3.0 KCl, and 1.0 MgCl 2 .
Microdialysis technique
Brain microdialysis experiments were performed in awake and freely moving animals, according to a protocol previously described (Lidö et al., 2009) . Briefly, rats were anaesthetized by isoflurane (Apoteket AB, Sweden), mounted into a stereotaxic instrument (David Kopf Instruments) and put on a heating pad to prevent hypothermia during surgery. Holes were superficially drilled for placement of two anchoring screws and one I-shaped dialysis probe (for Experiment 1 and 2, custom made in the laboratory) or a pre-manufactured I-shaped guide cannula in order to allow for a longer period of recovery following surgery (Experiment 3; AgnTho's, Lidingö, Sweden). The dialysis probe or guide cannula were lowered into the nAc (coordinates for dialysis probe: A/P: +1.85, M/L: −1.4, D/V: −7.8; for guide cannula: A/P: +1.85, M/L: −1.4, D/V: −5.8; (Paxinos and Watson, 2007) . The exposed length of the dialysis membrane was 2 mm.
The dialysis probe or guide as well as the anchoring screws were fixed to the scull with Harvard cement (DAB Dental AB, Sweden). After surgery, the rats were allowed to recover for two days (Experiment 1 and 2) before the dialysis experiment was initiated or seven to nine days before active systemic treatment was initiated (Experiment 3) (see Fig. 1 for experimental timeline). The longer period of recovery in experiment 3 was needed to minimize the influence of the surgical procedure on the voluntary ethanol consumption during repeated acamprosate treatment. On the experimental day, the sealed inlet and outlet of the probes were cut open and connected to a micro-perfusion pump (U-864 Syringe Pump, AgnTho's, Sweden) via a swivel allowing the animal to move around freely. In experiment 3, a pre-manufactured dialysis probe (10 mm in length, 6000 Da in membrane cut-off) was inserted into the guide cannula, resulting in a 2 mm exposed membrane length, the dialysis probe was then connected to a swivel as described above. All probes were perfused with Ringer solution at a rate of 2 μl/ min and dialysate samples (40 μl) were collected every 20 min. The rats were perfused with Ringer solution for at least 1 h in order to obtain a balanced fluid exchange before baseline sampling began. Animals were sacrificed directly after the experiment, brains were removed and probe placement was verified using a vibroslicer (Campden Instruments; Fig. 1 ).
Biochemical assay
To analyse the dopamine content of the samples, a high-pressure liquid chromatography system was used for the separation and detection of dopamine as described in Lidö et al. (2009) . To identify the dopamine peak, an external standard was used containing 3.25 fmol/μl of dopamine. When at least three consecutive stable values of dopamine were obtained ( ± 5%), the first drug was introduced.
2.5. Experimental procedure 2.5.1. Experiment 1: effects of acute administration of acamprosate and ethanol on nAc dopamine levels in naïve rats Acamprosate (0.5 mM in the perfusate), ethanol (300 mM), acamprosate and ethanol (acamprosate alone for 40 min after which ethanol and acamprosate were co-perfused) or Ringer was locally perfused in the nAc in ethanol naïve rats.
Experiment 2: effects of acute administration of acamprosate and ethanol on nAc dopamine levels in rats administered with acamprosate or vehicle for two days
Naïve animals were treated with acamprosate (200 mg/kg) or vehicle (0.9% NaCl, 2 ml/kg) i.p for two days. The animals received their first systemic injection on the day of implantation of the microdialysis probe. On the day of the microdialysis experiment a systemic injection of acamprosate was delivered, 40 min before the animals were challenged with either ethanol (1 g/kg) or tap water intragastrically (2 ml/ kg).
2.5.3. Experiment 3: effects of acute administration of acamprosate and ethanol on nAc dopamine levels in ethanol preferring rats administered with acamprosate or vehicle for ten days
In experiment 3 animals were placed in a voluntary ethanol consumption paradigm (Fahlke, 1994) in accordance with previous studies using acamprosate (Chau et al., 2010b) . In addition to the water bottle, the rats were presented with a bottle containing an ethanol solution. The ethanol concentration was gradually increased (2-4-6% v/v) over a two-week period. After one week of access to 6% ethanol in addition to the bottle of tap water, the rats were housed individually in plastic cages (40 × 24 × 15 cm). They had continuous access to two bottles containing either tap water or 6% ethanol solution. Bodyweight, water and ethanol intake were measured twice a week over a six-week period. The amount (g) of ethanol solution consumed, in percent of total fluid intake (g), was used as an index of ethanol preference. Animals were classified as ethanol low-(drinking < 20% of their daily fluid intake from the ethanol bottle), medium-(20-60%), or high-(> 60%) preferring based on the average ethanol preference during the last three of the six weeks. Only medium-and high-preferring animals were used for the rest of the experiment. Animals included in the study were placed on a limited access schedule where they had access to the bottles 2.5 h each day (at 9 am, 1 h after lights were turned off in the room), and water and ethanol intake was measured on a daily basis. On day four when monitoring the baseline of ethanol consumption in the limited access paradigm the rats were equipped with pre-manufactured guides for dialysis probes When a stable ethanol intake ( ± 25% over three days) was established (post-surgery and after at least ten days of ethanol consumption on limited access), the rats were divided equally, based on their ethanol intake, into two treatment groups and received either 200 mg/kg acamprosate or saline (2 ml/kg) i.p. Thirty minutes later, the rats were given access to the bottles of fluid. Following a total of ten days of acamprosate/vehicle treatment the rats underwent in vivo microdialysis. On the day of the dialysis experiment all rats received an injection of acamprosate (200 mg/kg i.p.) 100 min before ethanol (300 mM) was perfused in the nAc until the end of the experiment (see Fig. 2 for a schematic overview of the experiments).
Statistics
The dopamine content in each sample was expressed as the percentage of the average pre-treatment baseline. Data is presented as mean ± SEM. All microdialysis data were statistically analyzed using two-way ANOVA (analysis of variance) with repeated measures (time vs treatment group) followed by Tukey's multiple comparisons post hoc test, or, when appropriate a one-way ANOVA or paired t-test was used. Two-way ANOVA with repeated measures was also used in the statistical analysis for the voluntary ethanol intake (Experiment 3) for the between-and within-group comparisons. A probability (p) value < 0.05 was considered statistically significant.
Results
Acute administration of acamprosate prevents ethanol from further elevating nAc dopamine in naïve rats
In line with our previous studies, ethanol (Blomqvist et al., 1993; Ericson et al., 2003) as well as acamprosate (Chau et al., 2010a) increased nAc dopamine output ( Fig. 3a and b ; ANOVA with repeated measures revealed a time effect F (9,360) = 19, a treatment effect F (3,40) = 14.2 and an interaction effect F (27,360) = 3.6, all significant (p < 0.0001)). To evaluate a possible interaction between the dopamine-elevating properties of acamprosate and ethanol, we first applied acamprosate locally in the nAc and 40 min later ethanol was co-applied. Statistical analysis revealed that ethanol did not further increase dopamine levels in animals pre-treated with acamprosate ( Fig. 3c ; oneway ANOVA followed by Tukey's at time-point 80; ANOVA F (3,40) = 10.79, p < 0.001, post hoc analysis showed a significant increase of dopamine in all treatment groups compared to Ringer: ethanol vs Ringer p = 0.003, acamprosate vs Ringer p = 0.001, acamprosate + ethanol vs Ringer p < 0.001 whereas no difference was observed between acamprosate vs acamprosate + ethanol p = 0.612).
3.2. Acamprosate prevents ethanol from further elevating nAc dopamine in rats pre-treated with acamprosate for two days
In the second study we wanted to investigate whether repeated P. Chau et al. Pharmacology, Biochemistry and Behavior 175 (2018) 101-107 administration of acamprosate altered the nAc dopamine output observed following concomitant treatment with acamprosate and ethanol. We used three days of acamprosate treatment since we as well as others found that acamprosate robustly decreases voluntary ethanol intake at this time (Chau et al., 2010b; Cowen et al., 2005; Lidö et al., 2012) . Again, ethanol, this time by oral administration, was unable to increase extracellular nAc dopamine levels in rats pretreated with acamprosate ( Fig. 4a and b ; ANOVA with repeated measures disclosed a time effect F (9,225) = 7.5 (p < 0.001), a treatment effect F (3,25) = 3.9 (p = 0.020) and an interaction effect F (27,225) = 1.8 (p = 0.013)). At time-point 80 it was clear that ethanol or acamprosate increased dopamine, but when combined not further escalated the extracellular dopamine levels ( Fig. 4c ; one-way ANOVA followed by Tukey's at time-point 80; ANOVA F (3,25) = 6.05, p = 0.003, Tukey's: ethanol vs water p = 0.030, acamprosate vs acamprosate + ethanol p = 0.198).
Acamprosate is unable to prevent ethanol-induced dopamine elevation in ethanol-preferring rats treated with acamprosate for ten days
In the final study we wanted to investigate nAc dopamine in rats where acamprosate no longer produced an ethanol intake-reducing effect. To this end, we needed to confirm that acamprosate indeed decreased ethanol consumption and that the effect was lost over time. Thus, we used Wistar rats in a limited access voluntary ethanol consumption paradigm. Ethanol medium-and high-preferring rats were used and the daily fluid intake was measured over the baseline period and during a treatment period. The water intake did not differ between the groups, neither during baseline monitoring nor during the treatment period. Acamprosate treatment decreased ethanol intake during the initial treatment period ( Fig. 5a ; ANOVA with repeated measures showed a time effect F (12,372) = 6.7 (p < 0.0001), a treatment effect F (1,31) = 4.8 (p = 0.036) and an interaction effect F (12,372) = 3.3 (p = 0.0001) where post hoc analysis found an acamprosate-induced decrease of ethanol intake on day 2 (p = 0.006), 3 (p = 0.015) and 4 (p = 0.007). From day five of acamprosate treatment there was no longer any significant difference in ethanol intake as compared to vehicle treatment.
On the day of the dialysis experiment, all animals were given an acute, systemic injection of acamprosate (200 mg/kg i.p.) followed by local (nAc) ethanol perfusion (300 mM), while extracellular levels of dopamine were measured. Statistical analysis revealed a significant difference over time (ANOVA with repeated measures F (9,162) = 4.0 (p = 0.0001), but no treatment effect (F (1,18) = 2.2 (p = 0.152)) or interaction (F (9,162) = 0.6 (p = 0.748); Fig. 5b ). However, when further exploring the data we found that the systemic injection of acamprosate only elevated extracellular dopamine in the vehicle treated animals (p = 0.018 paired t-test between time-point 0 and 20 in rats receiving daily vehicle treatment and p = 0.066 in rats receiving daily acamprosate treatment). To further examine whether the long-term acamprosate treatment had any impact on ethanol-induced modulation of dopamine we employed another paired t-test between time-points 100 and 140 (the immediate time-point before ethanol perfusion and when Fig. 3 . Extracellular dopamine levels in the nucleus accumbens (nAc), as measured by in vivo microdialysis in freely moving and awake male Wistar rats. A) Rats received vehicle (Ringer) as indicated by the first arrow and the addition of ethanol (300 mM perfused in the nAc) or vehicle as indicated by the second arrow. B) Rats received acamprosate (0.5 mM) as indicated by the first arrow and the addition of ethanol (300 mM perfused in the nAc) or vehicle as indicated by the second arrow. The bar graph (C) demonstrates dopamine levels at time-point 80, i.e. 40 min after the addition of ethanol. Shown are the means ± SEM; n = 8 to 13, * = p < 0.05. Fig. 4 . Extracellular dopamine levels in the nucleus accumbens (nAc), as measured by in vivo microdialysis in freely moving and awake male Wistar rats. All rats had prior to the dialysis experiment received two days of systemic injections with either saline (vehicle) or acamprosate (200 mg/kg). A, B) On the day of the dialysis experiment the animals received the same systemic injection as during the previous two days (as indicated by arrow 1), followed by oral administration of ethanol (1 g/kg) or water 40 min later. The bar graph (C) demonstrates dopamine levels at time-point 80, i.e. 40 min after the addition of ethanol. Shown are the means ± SEM; n = 8 to 13; * = p < 0.05. the expected maximum of ethanol-induced influence on dopamine occurs). Here we found that ethanol did not increase dopamine output in rats repeatedly treated with vehicle for 10 days and acute acamprosate during microdialysis (p = 0.145), in line with both previous experiments (experiments 1 and 2 above). However, in rats repeatedly treated with acamprosate for 10 days and acute acamprosate during microdialysis, ethanol did increase extracellular dopamine (p = 0.002) (Fig. 5b) .
Discussion
The data presented here demonstrate that acamprosate modestly elevates nAc dopamine and prevents a further dopamine elevation by ethanol. Further, this combined effect of acamprosate is lost after longterm administration, when tolerance has developed also to the ethanol intake reducing effect of the drug. Taken together these results suggest that dopamine neurotransmission is involved in the ethanol intake-reducing effect of acamprosate, a link previously hypothesized by us and others (Cowen et al., 2005; Chau et al., 2010b) .
In rats, acamprosate robustly decreases ethanol consumption in a wide variety of research models and ratlines (Boismare et al., 1984; Chau et al., 2010b; Cowen et al., 2005; Czachowski et al., 2001; Gupta et al., 2008; Olive et al., 2002; Simms et al., 2008; Spanagel et al., 1996) . However, studies have also demonstrated a loss of the initial ethanol intake-reducing effect of acamprosate already after a few days of treatment (Cowen et al., 2005; Vengeliene et al., 2010) . This phenomenon was also observed in our laboratory, where acamprosate treatment did not differ from vehicle treatment, with regard to ethanol intake, after four to five days of systemic injections (Lidö et al., 2012) . Previous studies from our research group, trying to unravel the mechanism of action underlying the dopamine-elevating and ethanol intake-reducing effects of acamprosate, found that GlyRs in the nAc mediate both the neurochemical and behavioral effects, since strychnine blocked the acamprosate-induced increase in dopamine and reversed the ethanol intake-reducing effect of the drug (Chau et al., 2010a (Chau et al., , 2010b . This led us to hypothesize that the acamprosate-induced influence on dopamine may correlate to the ethanol intake-reducing effect, or lack thereof. Indeed, the present study shows that once acamprosate no longer increases nAc dopamine, the compound's ethanol intake-reducing effect is lost.
Consistent with previous results, acute administration of acamprosate in naïve animals increased dopamine levels in the nAc (Olive et al., 2002; Cano-Cebrián et al., 2003; Chau et al., 2010a) . When ethanol was concomitantly administered with acamprosate, there was no additive effect on accumbal dopamine levels. A similar result was obtained in rats that were pre-treated with acamprosate for two days. In previous studies, where we modulated nAc GlyRs, we found that raising extracellular levels of glycine, either by perfusion of glycine in the nAc or by a glycine reuptake inhibitor, not only produced a modest elevation of dopamine and prevented ethanol from further increasing nAc dopamine output, but also decreased voluntary ethanol intake (Lidö et al., 2009; Molander et al., 2007) . Thus, based on the findings presented here, again we conclude that the small increase in nAc dopamine levels after activation of GlyRs in the same brain region prevents ethanol from further increasing dopamine output, strengthening the role of nAc GlyRs in ethanol-induced dopamine elevation as well as in modulation of ethanol intake in the rat.
Studies using taurine, another endogenous ligand for the GlyR, found that local administration in the nAc mimics the effects of ethanol on nAc dopamine output (Ericson et al., 2006) . Further, ethanol increases taurine in the nAc (Dahchour and De Witte, 2000; Li et al., 2008) , and when the ethanol-induced elevation of taurine is prevented no elevation of nAc dopamine can be observed . These observations are interesting also with regard to acamprosate, since this compound also increases extracellular taurine in the nAc (Dahchour and De Witte, 2000; Dahchour et al., 1994 Dahchour et al., , 1996 De Witte et al., 1994) . Furthermore, since acamprosate both increases taurine levels and structurally resembles the taurine molecule its interaction with GlyRs could be either direct and/or indirect, where the former alternative appears less likely, since a targeted study failed to demonstrate a direct interaction with GlyRs (Reilly et al., 2008) .
Here acamprosate, as compared to vehicle, decreased ethanol intake during the initial days of treatment after which the ethanol consumption did not differ significantly from that in vehicle-treated rats. This appears to correspond to the dopamine increasing properties of the drug, where acamprosate initially prevented ethanol from increasing dopamine levels further (experiments 1 and 2), which could be interpreted such that acamprosate substitutes for ethanol in the elevation of dopamine, leaving the animal with a diminished drive for further ethanol consumption. However, after a longer treatment period acamprosate lost both its ethanol intake-reducing effect and its dopamineelevating properties. Although we suggest that both acamprosate and ethanol may increase nAc dopamine after an initial elevation of extracellular levels of taurine ; the present study), the mechanisms underlying these taurine elevations may differ. In a study by Lidö et al. (2012) long-term pretreatment with acamprosate (producing tolerance to the ethanol intake reducing effect), abolished the acamprosate-induced increases of taurine and dopamine in the nAc, as determined by in vivo microdialysis. Further studies are needed to elucidate whether the lack of increased levels of taurine in long-term acamprosate-treated animals is responsible for the lack of dopamine elevation and loss of effect on ethanol intake. In all three experiments we used doses of acamprosate and ethanol previously tested, known to be effective and without adverse effects. We also purposely used different routes of administration in order to include a wider perspective in a limited number of animals. In the first study, drugs were administered by local perfusion in the nAc to mechanistically explore the co-application on a local level. In the second study, we administered the drugs intragastrically to mimic the route of administration in human patients whereas in the last experiment we administered acamprosate systemically (i.p.) in order to repeat the route of administration used in studies where tolerance developed to the ethanol intake reducing effect of acamprosate. Although somewhat different routes of administration/protocols were used in the present study the obtained results are consistent, strengthening the overall conceptual conclusions drawn from the experiments.
Acamprosate is used world-wide as a pharmacotherapy for patients with alcohol dependence. However, the clinical effect size of acamprosate is small (numbers needed to treat: 7.5 (Mann et al., 2004) , where the underlying reason for this has been suggested to be lack of compliance rather than ineffectiveness of the substance (Koeter et al., 2010) . In a meta-analysis by Koeter et al. (2010) 68% of the 2035 patients were mostly compliant in the beginning of the trial (during the initial month of treatment) whereas this number dropped to 51% during the first six months. Of all the studies included, early discontinuation of acamprosate treatment occurred in 50% of the patients and the reason for this is not clear. Taking the present study into consideration the question arises whether, at least in some patients, discontinuation is secondary to perceiving diminished effect of the drug due to neuroadaptations, as of above. However, another factor of influence may be the level of alcohol consumption at onset of treatment where some studies have found acamprosate to be more efficacious when given to highly dependent individuals, rather than less severely dependent patients (Kiefer and Mann, 2010) . Theoretically the degree of tolerance development to acamprosate could also differ between these categories, an issue that remains to be explored both in animals and in man.
Notably, although acamprosate significantly decreased ethanol intake, the ethanol intake was never totally abolished. This might be explained by the findings of Czachowski and co-workers (Czachowski et al., 2001) , where acamprosate did not decrease the motivation to initiate ethanol intake but rather interfered with post-ingestive pharmacological stimuli. In other words, the animals were still motivated to taste ethanol, but would not continue drinking. This is in concordance with a clinical study (Hammarberg et al., 2009) , where acamprosatetreated patients that were challenged with a priming dose of alcohol choose not to continue drinking alcohol. However, in the same study acamprosate treatment had no effect on the "wanting" to ingest the initial alcohol dose (Hammarberg et al., 2009 ). This strengthens our hypothesis that acamprosate shares a dopamine-enhancing effect with ethanol and, to some extent, might even act as a substitution for ethanol in the nAc. However, although the acamprosate molecule in this respect appears to act in a similar manner as ethanol there are no indications that the molecule in itself is addictive.
In conclusion, acamprosate appears to reduce ethanol intake as long as it retains its dopamine-elevating ability. In the clinical setting, although factors like the patient's motivation to become fully abstinent from the start of the treatment influence the compliance to acamprosate, taking the present study into consideration it is possible that patients develop tolerance towards some of the effects of acamprosate and therefore regain the urge to consume alcohol. Whether it is N-acetylhomotaurinate or the calcium moiety of acamprosate (Spanagel et al., 2014) that mediates the effects here observed remains to be determined. Nevertheless, the ability of acamprosate to influence dopamine appears to be involved in its effect on ethanol consumption.
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